Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...

High-resistance inspiratory muscle strength training, or IMST, can help strengthen your breathing muscles. Practicing it for ...

Scottish Medicines Consortium approves new NHS Scotland drugs for lung cancer, leukaemia, cervical cancer, pulmonary ...

Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...

A recent study published in CHEST found that treatment-naïve adults with obesity-hypoventilation syndrome receiving a ...

The Scottish Medicines Consortium said it had accepted five out of six newly-licensed medicines under consideration ...

Plus, when to see a doctor.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify ...

Wearable device data may help detect and track idiopathic pulmonary arterial hypertension, a rare lung disease, a study ...

Nationally, there has been a rise in the number of children and adolescents with congenital and acquired heart disease ...

Earth can satisfy man’s need but not his greed” – Mahatma Gandhi Twenty-four percent of all global deaths, about 13.7 million ...